ConforMIS Inc (NASDAQ:CFMS) CEO Mark A. Augusti sold 6,807 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $3.53, for a total value of $24,028.71. Following the completion of the transaction, the chief executive officer now directly owns 1,116,891 shares in the company, valued at $3,942,625.23. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of NASDAQ CFMS traded down $0.13 during midday trading on Friday, hitting $3.42. 934,655 shares of the stock traded hands, compared to its average volume of 1,681,277. The stock has a market capitalization of $232.09 million, a price-to-earnings ratio of -4.62 and a beta of 3.05. The company has a debt-to-equity ratio of 0.64, a current ratio of 3.00 and a quick ratio of 2.33. ConforMIS Inc has a one year low of $0.36 and a one year high of $3.84.
ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of $20.64 million for the quarter, compared to analysts’ expectations of $20.11 million. ConforMIS had a negative return on equity of 97.85% and a negative net margin of 42.90%. Equities research analysts anticipate that ConforMIS Inc will post -0.43 EPS for the current year.
Several research firms recently issued reports on CFMS. Zacks Investment Research cut ConforMIS from a “buy” rating to a “hold” rating in a research report on Monday, May 6th. Oppenheimer set a $4.00 price objective on ConforMIS and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $3.00 price objective on shares of ConforMIS in a research report on Thursday, May 2nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $3.00.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of ConforMIS by 100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 20,000 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 10,000 shares during the period. Northern Trust Corp lifted its holdings in shares of ConforMIS by 8.6% during the 1st quarter. Northern Trust Corp now owns 154,390 shares of the medical instruments supplier’s stock valued at $444,000 after buying an additional 12,283 shares during the period. Morgan Stanley lifted its holdings in shares of ConforMIS by 197.3% during the 1st quarter. Morgan Stanley now owns 20,079 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 13,325 shares during the period. MML Investors Services LLC bought a new position in shares of ConforMIS during the 1st quarter valued at $58,000. Finally, Larson Financial Group LLC lifted its holdings in shares of ConforMIS by 588.6% during the 1st quarter. Larson Financial Group LLC now owns 24,100 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 20,600 shares during the period. 30.35% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Zolmax and is the property of of Zolmax. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://zolmax.com/investing/conformis-inc-cfms-ceo-sells-24028-71-in-stock/3089334.html.
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee.
Featured Story: How are dividend achievers different from dividend aristocrats?
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.